Pharmacokinetics of CPU0213, a novel endothelin receptor antagonist, after intravenous administration in mice

Acta Pharmacologica Sinica

Volumn 27, Issue 3, 2006, Pages 367-371

  Guan, Li ^a   Feng, Yu ^a   Ji, Min ^a   Dai, De Zai ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Acute toxicity; CPU0213; High pressure liquid chromatography; Mice; Pharmacokinetics

Indexed keywords

CPU 0213; ENDOTHELIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; COMPARTMENT MODEL; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PARAMETER; QUANTITATIVE ANALYSIS;

ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HALF-LIFE; INJECTIONS, INTRAVENOUS; LETHAL DOSE 50; MALE; MICE; MOLECULAR STRUCTURE; PYRAZOLES; RECEPTORS, ENDOTHELIN; VASOCONSTRICTOR AGENTS;

EID: 33644829032     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00288.x     Document Type: Article

References (18)

1. Yanagisawa M Kurihara H Kimura S Tomobe Y Kobayashi M Mitsui Y et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 1988 33 411 5
2. Miyuachi T Goto K. Heart failure and endothelin receptor antagonists Trends Pharmacol Sci 1999 20 210 7
3. Schiffrin EL. Role of endothelin-1 in hypertension Hypertension 1999 34 876 81
4. Boffa JJ Tharaux PL Dussaule JC Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism Hypertension 2001 37 490 6
5. Luscher TF Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs Circulation 2000 102 2434 40
6. Ray A Hegde LG Chugh A Gupta JB. Endothelin receptor antagonists: current and future perspectives Drug Discov Today 2000 5 455 64
7. B of compound 0213 J China Pharm Univ 2004 35 552 7
8. Clozel M Breu V Gray GA Kalina B Loffler BM Burri K et al. Pharmacological characterization of Bosentan, a new potent orally active nonpeptide endothelin receptor antagonist J.Pharmacol Exp Ther 1994 270 228 35
9. Huang M Ji M Dai DZ. The endothelin receptor antagonist 0213 reduces L-thyroxine cardiac hypertrophy and inhibits calcium mobilization in vascular smooth muscle contraction Drug Develop Res 2002 55 12
10. Huang M Qi JS Dai DZ. Long-term treatment with the novel non-peptide endothelin receptor antagonist 0213 in rats with chronic heart failure Drug Develop Res 2002 55 24
11. Liu Q Dai DZ. Influence of a new endothelin receptor antago-nistCPU0213 on expression of MMPs mRNA and TIMPs mRNA in rats with hypertrophic myocardium induced by L-thyroxin Chin J Clin Pharmacol Ther 2004 9 281 4 Chinese
12. Liu Q Ji M Dai DZ. Matrix metalloproteinases changes in rat hypertrophic myocardium induced by levothyroxine and the effect of a new endothelin receptor antagonist CPU0213 J China Pharm Univ 2004 35 150 5 Chinese
13. Bliss CI. The calculation of the dosage-mortality curve Ann Appl Biol 1935 22 134 67
14. Akaike H. A new look at the statistical model identification IEEE Trans Automat Contr 1974 19 716 23
15. Dai DZ Yu F Wang YQ Savage A. Clinical pharmacology Beijing The Pharmaceutical Science Publishing House of China 2002
16. Zhu Y Chen DD Su L Dai DZ. Assay of negative inotropism of bepridil on isolated guinea pig left atrial myocardium by simulating constant rate of absorption and elimination Acta Pharmacol Sin 1993 14 161 4 Chinese
17. Sintetos AL. Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolus Clin Pharmacol Ther 1987 41 112 7
18. Paalzow LK Paalzow GHM Tfelf-Hansen P. Variability in bioavailability: concentration versus effect In Rowland L editor Variety in drug therapy, description, estimation and control New York Raven Press 1985 p 167 84